Astrocytic calcium signaling plays pivotal roles in the maintenance of neural functions and neurovascular coupling in the brain. Vascular endothelial growth factor (VEGF), an original biological substance of vessels, regulates the movement of calcium and potassium ions across neuronal membrane. In this study, we investigated whether and how VEGF regulates glutamate-induced calcium influx in astrocytes. We used cultured astrocytes combined with living cell imaging to detect the calcium influx induced by glutamate. We found that VEGF quickly inhibited the glutamate/hypoxia-induced calcium influx, which was blocked by an AMPA receptor antagonist CNQX, but not D-AP5 or UBP310, NMDA and kainate receptor antagonist, respectively. VEGF increased phosphorylation of PKCα and AMPA receptor subunit GluA2 in astrocytes, and these effects were diminished by SU1498 or calphostin C, a PKC inhibitor. With the pHluorin assay, we observed that VEGF significantly increased membrane insertion and expression of GluA2, but not GluA1, in astrocytes. Moreover, siRNA-produced knockdown of GluA2 expression in astrocytes reversed the inhibitory effect of VEGF on glutamate-induced calcium influx. Together, our results suggest that VEGF reduces glutamate-induced calcium influx in astrocytes via enhancing PKCα-mediated GluA2 phosphorylation, which in turn promotes the membrane insertion and expression of GluA2 and causes AMPA receptors to switch from calcium-permeable to calcium-impermeable receptors, thereby inhibiting astrocytic calcium influx. The present study reveals that excitatory neurotransmitter glutamate-mediated astrocytic calcium influx can be regulated by vascular biological factor via activation of AMPA receptor GluA2 subunit and uncovers a novel coupling mechanism between astrocytes and endothelial cells within the neurovascular unit.
glutamate and adenosine transmission within neurons and/or glial cells (Duan, Anderson, Stein, & Swanson, 1999; Panatier et al., 2011; Perea, Navarrete, & Araque, 2009; Tan et al., 2017) . As we have known, glutamate, a major excitatory neurotransmitter, induces astrocytes excitability associated with the increase in the intracellular concentration of calcium ions ([Ca 2+ ] i ) partly through activation of ionotropic glutamate receptors (iGluRs). The iGluRs contain the N-methyl-D-aspartate (NMDA), the α-amino-3-(5-methyl-3-oxo-1, 2-oxazol-4-yl) propanoic acid (AMPA), and the kainate (KA) receptors (Zhu & Gouaux, 2017) . The AMPA receptors consist of four subunits:
GluA1-GluA4 (formerly named as GluR1-GluR4) (Traynelis et al., 2010) . Among them, the GluA2 subunit is a critical regulator for calcium permeability in neurons (Bogaert et al., 2010; Gorter et al., 1997; Umeda et al., 2018) and glial cells (Beppu et al., 2013; Hoft, Griemsmann, Seifert, & Steinhauser, 2014) . In general, the GluA2-lacking AMPA receptors endow neural cells with calcium flux into the intracellular cytoplasm; conversely, the GluA2-containing AMPA receptors inhibit calcium influx. Therefore, the GluA2-lacking AMPA receptors and GluA2-containing AMPA receptors are referred as the calciumpermeable AMPA receptors and calcium-impermeable AMPA receptors, respectively (Hollmann, Hartley, & Heinemann, 1991; Liu & Cull-Candy, 2005; Noh et al, 2005; Santos et al, 2006; Traynelis et al., 2010) . The increase of [Ca 2+ ] i in astrocytes may result from the calcium influx through GluA2-lacking AMPA receptors and/or the release of intracellular calcium storage through activation of the inositol 1,4,5-trisphosphate (IP3) signaling pathway (Hamilton et al., 2008; Zorec et al., 2012) . GluA2-containing AMPA receptors inhibit calcium influx in neurons through PKC-mediated signaling pathway (Sun & Liu., 2007; Liu & Zukin, 2007) . The calcium signaling within the brain plays important roles in crosslink between neuronal activities and astrocytic functions (Panatier et al., 2011; Zorec et al., 2012) . Moreover, the movement of calcium ions in astrocytes contributes to the pathogenesis of acute brain injury. For example, ischemic cerebral stroke (Dong, He, & Chai, 2013; Rakers, Schmid, & Petzold, 2017) , traumatic brain injury (Gao et al., 2013; Maneshi, Sachs, & Hua, 2015) or epilepsy (Ding et al., 2007; Fellin, Gomez-Gonzalo, Gobbo, Carmignoto, & Haydon, 2006; Tian et al., 2005) can cause significant increase of the [Ca 2+ ] i in astrocytes.
Such increase can be blocked by glutamate receptor antagonists (Ding et al., 2007) or antiepileptic drugs (Tian et al., 2005) , which is accompanied with neuroprotection. It is plausible that disturbing astrocytic calcium homeostasis and gliotransmission result in dysfunction of the brain and/or cause specific disorders of the central nervous system (CNS).
However, it is unclear how calcium homeostasis and transmission in astrocytes are regulated.
As we have well known, astrocytes can secrete several neurotrophic factors, such as brain-derived neurotrophic factor (BDNF) (Koppel et al., 2018) , fibroblast growth factor (FGF) (Kajitani et al., 2015; Zhang et al., 2009) , and vascular endothelial growth factor (VEGF) (Ijichi, Sakuma, & Tofilon, 1995) . It has been reported that BDNF and FGF can modulate neurogenesis (Kang & Hebert, 2015) , brain development (Marte, Messa, Benfenati, & Onofri, 2017; Shimada, Yoshida, & Yamagata, 2016) . BDNF contributes to antidepressant effect (Li et al., 2018) and neural repair in disease brain (Xu, Lv, Dai, Lu, & Jin, 2018) . Moreover, BDNF enhances glutamate release from presynaptic nerve terminals in normal condition but protects neurons against excitotoxicity via reduction of glutamate-mediated calcium overload in neurons under disease condition (Lau, Bengtson, Buchthal, & Bading, 2015) . VEGF, especially VEGF-A, also possesses BDNF-like effects on neuronal function although it was originally as an endothelial growth factor with major function of angiogenesis and vascular endothelial permeability (Sun & Guo, 2005) . VEGF regulates neural development, including enhancing neuronal cell proliferation (Jin et al., 2002; Wang, Guo, Qiu, Feng, & Sun, 2007; Wuestefeld, Chen, Meller, Brand-Saberi, & Theiss, 2012) , differentiation (AvrahamLubin, Goldenberg-Cohen, Sadikov, & Askenasy, 2012; Wu et al., 2017) , transdifferentiation (Shen et al., 2016) , migration (Meissirel et al., 2011) , and plasticity Yang et al., 2017) . In addition, VEGF can regulate the activities of potassium channels (Qiu, Zhang, & Sun, 2003; Wu, Yang, Li, Liu, & Sun, 2015; Xu et al., 2003) and calcium channels (Ma et al., 2009 ) on neuronal membrane, thereby altering neuron excitability and protecting neurons against ischemic/hypoxic damage and excitotoxicity via activation of VEGF receptors (VEGFRs) (Bao, Lu, Wang, & Sun, 1999; Ruiz de Almodovar, Lambrechts, Mazzone, & Carmeliet, 2009; Sun & Guo, 2005) . VEGFRs belong to tyrosine kinase receptor (Holmes, Roberts, Thomas, & Cross, 2007; Claesson-Welsh, 2016 ) and mainly include VEGFR-1(Flt1), VEGFR-2 (Flk1/KDR) and VEGFR-3(Flt4). VEGF-A (also known as VEGF) can bind to Flt1 and Flk1 receptors, VEGF-C and VEGF-D bind to Flt4 receptor and mainly participate in regulation of angiogenesis and lymphangiogenesis (Pan et al., 2017; Shibuya, 2013) . VEGF modulates neuronal function mostly via activation of Flk1, but not Flt1 receptors in the brain (Carmeliet & Ruiz de Almodovar, 2013) . Moreover, VEGF and its receptors are induced to highly express in astrocytes during the pathophysiological process of neurodegenerative diseases (Barbeito et al., 2010; Hsiao et al., 2015; Spampinato, Merlo, Sano, Kanda, & Sortino, 2017; Vijayalakshmi et al., 2015) and ischemic/hypoxic injury (Ijichi et al., 1995; Shin et al., 2008) , in which activation of VEGFR2/Flk1 is protective (Freitas-Andrade, Carmeliet, Stanimirovic, & Moreno, 2008) .
In the present study, we determined whether VEGF regulates glutamate-induced calcium influx in astrocytes and investigated the underlying molecular mechanisms. We used living cell imaging to detect the changes of [Ca 2+ ] i levels and with pHluorin-tagged GluA1
(pH-GluA1)/pHluorin-tagged GluA2 (pH-GluA2) to track the plasma membrane insertion of GluA1/GluA2 in cultured astrocytes. We found that VEGF inhibited glutamate-induced calcium influx via increase of GluA2 phosphorylation and membrane insertion through activation of PKC in astrocytes. These results revealed that biological factor released from vascular endothelial cells also participated in the modulation of astrocytic calcium influx via activation of glutamate receptor subunit GluA2. Our results help us to understand functional and biochemical coupling mechanism within the neurovascular units in the mammalian brains.
| MATERIALS AND METHODS

| Reagents
VEGF 165 (VEGF), SU1498, UBP310, rabbit monoclonal anti-GluA2, goat polyclonal anti-Flk1, and anti-mouse IgG-Cy5 were purchased from Abcam (Cambridge, UK). Rabbit polyclonal anti-phospho-PKCα (Thr638, p-PKCα), rabbit monoclonal anti-PKCα, and rabbit polyclonal anti-GluA1 were purchased from Abways Technology (Shanghai, China 
| Culture of cortical astrocytes
Cultured astrocytes were prepared from cerebral cortices of newborn Sprague-Dawley rats (2 days old) (Department of Laboratory Animal Science, Fudan University) as reported previously (Gao et al., 2013; Shi et al., 2017 ) with a small adjustment. In brief, after removal of meninges and olfactory bulb neopallia were cut into small cubes (1 mm 
| Protein preparation
| Immunoprecipitation
| Cell transfection and pHluorin assay 2.5.1 | Cell transfection
For visualizing the membrane insertion of GluA1 and GluA2, astrocytes were transfected with plasmid-encoding N terminus of GluA1/ GluA2 tagged with pH-sensitive fluorescent protein ("pHluorin") (pRK5-pH-GluA1/A2, pH-GluA1/A2) (Araki, Lin, & Huganir, 2010) .
For knockdown GluA2 expression, astrocytes were transfected with a specific pool of three different siRNA duplexes (5 0 -GCA UAU UUC UGU CCU CCU UTT-3 0 ; 5 0 -GCA GGU GAC UGC UAU CAA UTT-3 0 ; 5 0 -GCA CAC ACA GCG ACA AUU ATT-3 0 , Gene Pharma, Shanghai, China) against GluA2 or a non-specific siRNA (scramble, 5 0 -UUC UCC GAA CGU GUC ACG UTT-3 0 ).
Plasmids and siRNA were respectively transfected using lipofectamine 2000 system. In brief, astrocytes were passed into the 3.5 cm glass-bottomed cell culture dishes or 96-well plates and cultured in the antibiotic-free culture medium. One day after incubation, the cultured astrocytes were transfected with plasmids (final concentration of 1 μg/mL) and siRNA (50 nM) using lipofectamine 2000 system (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol.
The astrocytes transfected with plasmids were used for pHluorin assay during 24-48 hr after transfection, and the astrocytes transfected with siRNA were used for analyzing the effects of VEGF on calcium influx with fluorescence microplate reader at 48 hr after transfection.
| Living cell pHluorin assay
The pHluorin assay was processed as reported before with small adjustment (Araki et al., 2010) . The growth media was substituted with imaging buffer (119 mM NaCl, 25 mM HEPES, 10 mM D-glucose, 2 mM NaHCO 3 , 2.5 mM KCl, 1 mM NaH 2 PO 4 , 2.5 mM CaCl 2 , 1.3 mM MgSO 4 , pH 7.4). To investigate whether VEGF modulates GluA1 or GluA2 insertion, VEGF (50 ng/mL) was supplied to the imaging buffer 20 min before data acquisition. In analyzing whether VEGF' effect on GluA2 insertion was related to Flk1 activation, SU1498 (20 μM) was supplied to imaging buffer 20 min before VEGF application. The pHluorin was detected from a single confocal plane at excitation and emission wavelength of 488 nm and 525 nm by using a Leica SP8 confocal microscope. Images of 1,024 × 1,024 pixels were collected at a rate of 12 per min for 10 min. All imaging experiments were performed at 37 C by using a heating system.
| Insertion analysis
Recordings were analyzed using Image J software. After import to Image J, the images were background corrected and noise filtered using the Gaussian blur (Sigma = 1). In order to show the insertion events, y-t rendering images were generated by rotating the original
x-y-t image stack 90 along y-axis using maximum intensity projection algorithm (MIP) of Image J and the maximum intensity of each x line was projected onto a single pixel of the y-axis. This algorithm exhibited the original images in a single image and displayed the insertion event in a "line" like shape-the insertion events were appear as horizontal lines. The y-t rendering images were displayed the time on "x" axis (time passes from left to right of image) and the insertion events lasting over 10 s were registered as insertion events manually. Total events per 10 min were taken as the frequency of insertion.
| Intracellular calcium measurement
The intracellular calcium level was quantified using either inverted microscopy (DMI4000, Leica, Wetzlar, Germany) or fluorescence microplate reader (Thermo Fisher Scientific, Waltham, MA) as previously described with small adjustment (Hemstapat, Smith, & Monteith, 2004; Ma et al., 2009) . Briefly, cultured astrocytes were grown in 3.5 cm glass-bottom culture dish or 96-well plate were prepared for 
| In-cell Western analysis
In-cell Western was performed as previously described with a small modification (Pandey et al., 2015) . After calcium measurement, the astrocytes transfected with GluA2 siRNA or scramble non-target siRNA were washed thoroughly in cold PBS, fixed with 4% paraformaldehyde in PBS for 20 min, blocked with PBS buffer containing 0.3% Triton X-100 and 10% fetal calf serum for 90 min at room temperature. Then, the astrocytes were incubated with rabbit anti-GluA2 To investigate the molecular mechanism of VEGF's effect, astrocytes
were incubated with CNQX (20 μM), D-AP5 (100 μM) or UBP310
(10 μM) for 20 min before VEGF treatment.
| Statistics
All of the statistical tests were performed using SPSS 9.0 (IBM, Chicago, IL), or Sigma plot. The significance of the differences among multiple groups were analyzed via one-way ANOVA followed by Fisher's least significant difference (LSD Figure 1b) . Interestingly, we also found that VEGF treatment significantly increased the serine phosphorylation of AMPA receptor subunit GluA2, but not GluA1 in astrocytes, while it had no effect on total GluA1 and GluA2 protein levels (Figure 1c,d ). VEGF treatment increased the serine phosphorylated GluA2 levels to 4.32 ± 0.71 times at 1 min, 3.23 ± 0.40 at 20 min and turned to baseline at 30 min, compared to vehicle treatment (Figure 1d ). Moreover, VEGF (20 min, 50 ng/mL)-increased GluA2 serine phosphorylation was completely blocked by co-incubation with SU1498, an antagonist for VEGF Flk1 receptor, and the antagonist alone had no effect on the GluA2 serine phosphorylation (Figure 1e ,f).
| VEGF increases membrane insertion and expression of AMPA receptor GluA2 subunit in astrocytes
To explore the effect of VEGF on GluA1 and GluA2 membrane insertion in astrocytes, we used living cell imaging to detect fluorescent signals of pHluorin-tagged GluA1/GluA2, which shows fluorescence at the neutral extracellular surface and non-fluorescence in acidic intracellular vesicular compartments (Araki et al., 2010) , and analyzed the membrane insertion events of GluA1/GluA2 based on appearance of fluorescent signals within 10 min recordings in each single astrocyte (Figure 2a) . We found that VEGF treatment (20 min, 50 ng/mL) FIGURE 1 VEGF increases serine phosphorylation of AMPA receptor GluA2 subunit in astrocytes via activation of Flk1 receptor. (a-d) Total cellular proteins from cultured astrocytes with different VEGF treatment times were precipitated with antibodies against Flk1, Flt1, GluA1 or GluA2. The immunoprecipitates were examined by Western blot with antibodies against phosphotyrosine (PY20) or phosphoserine (pSer) to detect tyrosine phosphorylated Flk1 (a, p-Flk1) or Flt1 (b, p-Flt1), and serine phosphorylated GluA1 (c, p-GluA1) or GluA2 (d, p-GluA2). Then the blots were reprobed with antibodies against Flk1, Flt1, GluA1 or GluA2 to detect the total protein loading (a, t-Flk1, b, t-Flt1, c, t-GluA1 d, tGluA2). The relative quantity of phosphorylated Flk1, Flt1, GluA1 or GluA2 was calculated as p-Flk1/t-Flk1, p-Flt1/t-Flt1, p-GluA1/t-GluA1 or p-GluA2/t-GluA2. (e, f) Total cellular proteins from cultured astrocytes with 20 min different treatments were precipitated with an antibody against GluA2. The immunoprecipitates were examined by Western blot with an antibody against phosphoserine to detect phosphorylated GluA2. Then the blots were reprobed with antibody against GluA2 to detect the total loading of GluA2 protein. The relative quantity of phosphorylated GluA2 was calculated as p-GluA2/t-GluA2. C: Vehicle; V: VEGF; V + S: VEGF + SU1498; S: SU1498. To make sure equal proteins were used for immunoprecipitation, 10% amount of proteins (input) for immunoprecipitation from each group were electrophoresed and immunoblotted with antibodies against Flk1, Flt1, GluA1 or GluA2. N = 4 in (a, b, d, f). N = 3 in (c). * p < 0.05 vs. vehicle group; *** p < 0.01 vs. vehicle group; ### p < 0.01 vs. VEGF group significantly increased the GluA2 insertion events in astrocytes (29.24 ± 2.60) compared with vehicle treatment (16.41 ± 3.27). The increase in the GluA2 insertion events induced by VEGF was completed abolished by co-incubation with SU1498 (Figure 2b,c) . The same VEGF treatment had no effect on the GluA1 insertion events (Figure 2d,e) . Next, we extracted the membrane fraction of the astrocytes to examine the effect of VEGF treatment (20 min, 50 ng/mL) on GluA2 membrane expression using Western blot analysis. We showed that the VEGF treatment significantly increased the membrane expression of GluA2 in astrocytes compared with vehicle treatment and that this VEGF effect was dramatically inhibited by co-incubation with SU1498, while the antagonist alone had no effect on GluA2 membrane expression (Figure 2f,g ). Moreover, VEGF treatment increased the ratio of membrane GluA2/membrane GluA1 (mGluA2/ mGluA1) to 2.12 ± 0.21 times compared with vehicle treatment (Figure 2h,i) .
| VEGF increases serine phosphorylation of AMPA receptor GluA2 subunit in astrocytes via activation of PKCα signaling pathway
To further analyze the mechanism of VEGF-induced serine phosphorylation of GluA2, we carried out the following experiments. Firstly we conducted triple immunostaining with antibodies against Flk1, GluA2 and GFAP (a marker for astrocytes) in cultured astrocytes.
We observed that GFAP positive astrocytes were co-labeled with GluA2 and Flk1 (Figure 3a) , suggesting that both Flk1 and GluA2 receptors are expressed in astrocytes. Secondly, we conducted coimmunoprecipitation to examine if Flk1 and GluA2 receptors directly bind to each other. Whole cell extracts were immunoprecipitated with antibody against GluA2, and then immunoblotted with antibody against Flk1. Our results showed that the anti-GluA2 antibody did not pull down Flk1 (Figure 3b) , suggesting that Flk1 and GluA2 did Flk1 antagonist SU1498, while the antagonist alone had no effect on PKCα phosphorylation (Figure 3d ). Fifthly, we further showed that coincubation with calphostin C, a PKC inhibitor, significantly abolished serine phosphorylation of GluA2 induced by VEGF, while the inhibitor alone had no effect on GluA2 phosphorylation (Figure 3e ).
| VEGF inhibits glutamate-induced calcium influx in astrocytes via activation of AMPA receptor GluA2 subunit and PKC signaling
To further analyze whether VEGF inhibits glutamate-induced calcium influx in astrocytes and its possible mechanism, we conducted living cell imaging to investigate the effect of VEGF under different conditions. We first observed that glutamate (100 μM) induced a rapid increase in Fluo-4 fluorescence in astrocytes of the control group (left column, Figure 4a ). Using this model, we found that VEGF treatment significantly diminished the glutamate-induced calcium influx in astrocytes, and the effect of VEGF was completely blocked by SU1498, while the antagonist alone had no effect on the glutamate-induced calcium influx (Figure 4b,c) . As a control, we observed that VEGF lost such inhibitory effect in calcium-free perfusion buffer (Figure 4d Furthermore, we also found that the inhibition of calcium influx produced by VEGF was completely blocked by pretreatment with calphostin C while this PKC inhibitor alone had no effect on the glutamate-induced calcium influx (Figure 4g,h ).
3.5 | Knockdown of AMPA receptor GluA2 subunit reverses inhibitory effect of VEGF on glutamateinduced calcium influx in astrocytes Next, we investigated the effect of knockdown of GluA2 subunit on the VEGF-inhibited calcium influx in astrocytes. The GluA2 subunit in astrocytes was knocked down by a specific siRNA pool. As shown in Figure 5a , at 48 hr after transfection with the siRNA pool, the level of GluA2 protein in astrocytes was reduced to 35.4% ± 1.7% compared to that in the scramble siRNA group, indicating that the siRNA pool is able to downregulate GluA2 expression in astrocytes. Then, using this knockdown approach, we found that the effect of VEGF-inhibited calcium influx was disappeared in astrocytes transfected with the GluA2 siRNA pool while it was still presented in astrocytes transfected with scramble non-target siRNA (Figure 5b ). And, we even observed that the GluA2 siRNA treatment enhanced the glutamate-induced calcium influx in astrocytes no matter whether astrocytes were treated with VEGF ( Figure 5b ). Following the calcium imaging, we performed in-cell
Western analysis with antibodies against GluA2 and β-actin to confirm siRNA-produced knockdown of GluA2 subunit in the imaging wells.
The fluorescent images in Figure 5c representing the results of in-cell
Western analysis in the wells with different treatments showed that the GluA2 siRNA pool, but not scramble non-target siRNA, effectively and statistically downregulated the GluA2 expression in the culture astrocytes (Figure 5d ).
| VEGF inhibits OGD-induced calcium influx in astrocytes via AMPA receptors
In order to explore the effect of VEGF on the changes in calcium influx during hypoxic/ischemic insults, we performed calcium-imaging analysis in astrocytes with OGD model, a popular ischemic/hypoxic in vitro model. We found that the Fluo-4 fluorescent signals in cultured astrocytes was increased after exposure to OGD (Figure 6a ).
The intracellular calcium signals in astrocytes were rapidly increased (Ma et al., 2009; Shen et al., 2016; Wu, Lv, Lei, Qian, & Sun, 2019) .
Our data from living cell imaging showed that VEGF-inhibited glutamate-induced calcium influx is completely blockaded by SU1498, an antagonist for Flk1 receptor, indicating that the inhibitory effect of VEGF on the glutamate-induced calcium influx is specifically via activation of Flk1 receptor (Figure 4b,c) . Present results further support that VEGF can modulate the calcium homeostasis in neuronal cells (El Ghazi et al., 2012; Ma et al., 2009 ) besides endothelial cells. However, effects of VEGF on the calcium homeostasis in different types of cells are not identical (Faehling et al., 2002; Kim et al., 2008; Meissirel et al., 2011) . The current study provides an evidence to support that VEGF is highly critical of the regulation of glutamate-mediated calcium signaling or calcium homeostasis in astrocytes.
It has been demonstrated that glutamate increases calcium influx via activation of iGluRs, including AMPA receptors, NMDA receptors, and KA receptors in neurons (Cornell-Bell, Finkbeiner, Cooper, & Smith, 1990; Hamilton et al., 2008) . In this study, we revealed that VEGF inhibits glutamate-induced calcium influx depending on the activation of AMPA receptors in astrocytes, because inhibitory effect of VEGF on glutamate-induced calcium influx is blocked by CNQX, an antagonist of AMPA receptor, but not D-AP5 or UBP310, antagonists of NMDA or KA receptor, respectively ( Figure 4f ). As we have known, AMPA receptors consist of four subunits: GluA1-GluA4. Among them, GluA1 subunit is in favor of calcium influx, and GluA2 subunit is against calcium influx (Pougnet et al., 2014) . Therefore, GluA2-lacking AMPA receptors allow calcium influx from extracellular space, whereas GluA2-containing AMPA receptors prohibit calcium influx. Using siRNAproduced specific knockdown approach, we identified that AMPA receptor GluA2 subunit mediates the inhibitory effect of VEGF on astrocytic calcium influx because siRNA-produced specific knockdown of GluA2 prevents VEGF-inhibited astrocytic calcium influx (Figure 5b ).
Serine phosphorylated GluA2 subunit preferentially retains on the surface membrane of neurons (Christian et al., 2012; States et al., 2008) . The increase of GluA2 expression on neural cell membrane reduces calcium permeability (Beppu et al., 2013) . In contrast, the decrease of membrane expression of GluA2 enhances calcium influx in neurons (Conrad et al., 2008) . Our data showed that, in astrocytes, VEGF increases serine phosphorylation (Figure 1d-f) , membrane insertion (Figure 2b, c) , and membrane expression of GluA2 (Figure 2f,   g ), but not GluA1 (Figures 1c and 2d,e) . By enhancing GluA2 phosphorylation and trafficking, VEGF increases the ratio of GluA2/GluA1 on cell membrane of astrocytes (Figure 2h, i) , thereby inhibiting glutamate-induced calcium influx.
PKC modulates GluA2 phosphorylation (Ahn & Choe, 2010) , membrane insertion (Christian et al., 2012; States et al., 2008) , and switch of synaptic AMPA receptors from GluA2-lacking (calciumpermeable) to GluA2-containing (calcium-impermeable) receptors in neurons (Sun & Liu, 2007) . PKC-mediated GluA2 phosphorylation can regulate its internalization in neurons of the CNS (Chung, Xia, Scannevin, Zhang, & Huganir, 2000; Park et al., 2009) . In the present study, we showed that VEGF increases PKCα phosphorylation, which can be blocked by SU1498 (Figure 3d ). And we also showed that coincubation with calphostin C (an inhibitor of PKC) completely blocked VEGF-induced GluA2 phosphorylation (Figure 3e ) and inhibition of calcium influx (Figure 4g, h) . These results suggest that the effects of VEGF on serine phosphorylation of GluA2 and calcium influx depend on the activation of PKC in astrocytes. Based on the present findings, we propose a signaling pathway for VEGF-inhibited astrocytic calcium influx as summarized in Figure 7 . VEGF inhibits glutamate-induced astrocytic calcium influx by activating its receptor Flk1 and then enhancing PKCα-mediated AMPA receptor GluA2 subunit phosphorylation at serine residues, which can promote membrane insertion and expression of GluA2. Through the increasing of GluA2 trafficking to the membrane, VEGF treatment will cause AMPA receptors to switch from calcium-permeable to calcium-impermeable, thereby inhibiting calcium influx in astrocytes (Figure 7 ).
We have known that ischemic insults both in vivo and in vitro (Dong et al., 2013; Duffy & MacVicar, 1996; Fern, 1998) increase intracellular concentration of calcium in astrocytes.
Present results revealed that OGD-induced increase of astrocytic calcium influx was dependent of activation of iGluRs since CNQX, D-AP5 and UBP310 respectively decreased the calcium influx (Figure 6a-d ).
Using this model, we further found that VEGF inhibited OGD-induced calcium influx via activation of AMPA receptor in astrocytes since only CNQX could block such inhibition of VEGF (Figure 6b-d) .
VEGF possesses a diversity of functions in a different type of cells. For modulation of calcium dynamics, VEGF increases calcium influx in endothelial cells via activation of extracellular signal-regulated kinase (ERK) 1/2 through the phospholipase γ-PKCα-Raf pathway (Olsson, Dimberg, Kreuger, & Claesson-Welsh, 2006) , whereas it reduces calcium currents and influx in neurons (Ma et al., 2009 ) via activation of nitric oxide (NO) production (El Ghazi et al., 2012) . It has been demonstrated that VEGF-increased endothelial calcium influx induces angiogenesis, which is beneficial to the reconstruction of cerebral vessels and resupplying blood flows to ischemic brains. Meanwhile, VEGF reduces glutamate-induced calcium influx in neural cells, which might be helpful for protection against excitotoxicity in neurons (Bogaert et al., 2010; Gorter et al., 1997; Liu et al., 2004) and astrocytes. Collectively, such diversity effects of VEGF in the vessels and neural cells might be required for the maintenance of brain homeostasis or self-protection especially during ischemic brain injury (Lin et al., 2015; Ruan, Wang, ZhuGe, & Jin, 2015; Wittko-Schneider, Schneider, & Plate, 2013 ). In addition, recent studies support that VEGF is an important coupling factor within endothelial cells as well as astrocytes and neurons in the CNS (Pan, Mao, & Sun., 2017; Wu et al., 2015 Wu et al., , 2017 Yang et al., 2017) . Given that glutamate is a very important excitatory neurotransmitter and VEGF is a vascular biological factor, our results demonstrated that VEGF inhibits the glutamate-induced calcium influx in astrocytes via activation of the PKCα-mediated signaling pathway, which further suggests that astrocytes in the brain possess capabilities to receive information from neighboring cells, endothelial and neuronal cells, and then initiate intracellular signaling pathways to regulate calcium signaling within neurovascular units.
ACKNOWLEDGMENTS
This work was supported by grants from National Nature Science Foundation of China (81030020, 81571197 and 81771268). 
